Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 601 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New on NCI’s Websites for December 2022 December 27, 2022 In the Name of Pinkness October 8, 2020 It’s a fair COP: Why our chief clinician went to a... December 13, 2021 Biomedical Engineering Student Invents Device for At-Home Breast Cancer Screening January 6, 2021 Load more HOT NEWS Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... Lung Cancer Death Rates Among Women in Europe Are Finally Levelling... FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
